São Paulo – Danish pharmaceutical company Novo Nordisk announced a leadership change in its Brazilian operations amid an ongoing legal dispute over the liraglutide patent, the active ingredient in drugs such as Ozempic.

Isabella Wanderley, who had led the company in Brazil since 2021, recently stepped down. According to Novo Nordisk, the move is part of a broader leadership transition process. Until a new head is appointed, operations in the country will be overseen by Allan Finkel, vice president for Latin America.

The change comes at a sensitive time for the company in Brazil. The validity of the liraglutide patent is being challenged in court after rulings allowed competitors to market similar products. The shift also reflects growing market pressures, including competition from Eli Lilly, and concerns over the upcoming loss of exclusivity for key molecules by 2026.

Source: Valor Econômico

Would you like a complete analysis on this? Contact us at pharmabrnews@gmail.com